Substance / Medication

Tarlatamab

Overview

Active Ingredient
tarlatamab
RxNorm CUI
2682954

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.
Mountzios Giannis, Sun Longhua, Cho Byoung Chul et al. · N Engl J Med · 2025
PMID: 40454646RCT
Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study.
Aggarwal Rahul, Rottey Sylvie, Bernard-Tessier Alice et al. · Clin Cancer Res · 2025
PMID: 40689871TrialFull text (PMC)
Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update.
Dowlati Afshin, Hummel Horst-Dieter, Champiat Stephane et al. · J Clin Oncol · 2024
PMID: 39208379TrialFull text (PMC)
Plain language summary: tarlatamab for patients with previously treated small cell lung cancer.
Ahn Myung-Ju, Cho Byoung Chul, Felip Enriqueta et al. · Future Oncol · 2024
PMID: 39530627TrialFull text (PMC)
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
Ahn Myung-Ju, Cho Byoung Chul, Felip Enriqueta et al. · N Engl J Med · 2023
PMID: 37861218Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tarlatamab (substance)
SNOMED CT
92911000087102
UMLS CUI
C5446797
RxNorm CUI
2682954

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.